UY24130A1 - Peptido p277 analogos, y composiciones farmaceuticas que los comprenden para el tratamiento o diagnostico de diabetes. - Google Patents
Peptido p277 analogos, y composiciones farmaceuticas que los comprenden para el tratamiento o diagnostico de diabetes.Info
- Publication number
- UY24130A1 UY24130A1 UY24130A UY24130A UY24130A1 UY 24130 A1 UY24130 A1 UY 24130A1 UY 24130 A UY24130 A UY 24130A UY 24130 A UY24130 A UY 24130A UY 24130 A1 UY24130 A1 UY 24130A1
- Authority
- UY
- Uruguay
- Prior art keywords
- peptide
- sequence
- hsp60
- treatment
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Veterinary Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a nuevos peptidos que son variantes de un epitopo de la proteína de shock de calor humana de 60kDa (hsp60) y a las composiciones farmacéuticas que la comprenden y a los métodos para el diagnostico y el tratamiento de diabetes mellitus (IDM) dependiendo de insulina, mediante el uso de dichos péptidos. Un péptido que tiene la estructura de la secuencia p277 de hsp60 en la que uno o ambos residuos de cisteina son remplazados por residuos de valina y/o en la que el residuo thr19 es remplazado lys, que tiene sustancialmente la misma actividad biológica que p277 pero con estabilidad sustancialmente mejorada. Los nuevos análogos p277 pueden usarse para cualquier propósito en el que pueden usarse p277. Un equipo para diagnosticar la presencia de IDDM sometido a ensayo la presencia de anticuerpos anti hsp60 de acuerdo con el método que comprende: a- un antigeno que es un péptido de la secuencia (I); y b- un anticuerpo marcado que es capaz de reconocer la región no variable de dichos anticuerpos anti hsp60 que deben ser detectados. Una composición farmacéutica que comprende un péptido de secuencia, y un portador farmacéuticamente aceptable. Un método para la prevención o tratamiento de IDDM que comprende administrar a un sujeto humano una cantidad eficaz de un péptido de secuencia l, en un portador apropiado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL11209494A IL112094A0 (en) | 1994-12-21 | 1994-12-21 | Novel peptides and pharmaceutical compositions comprising them |
IL11446095A IL114460A0 (en) | 1995-07-05 | 1995-07-05 | Peptide p277 analogs and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
UY24130A1 true UY24130A1 (es) | 1996-06-11 |
Family
ID=26322965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY24130A UY24130A1 (es) | 1994-12-21 | 1995-12-21 | Peptido p277 analogos, y composiciones farmaceuticas que los comprenden para el tratamiento o diagnostico de diabetes. |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP0820303B1 (es) |
JP (2) | JP3420245B2 (es) |
KR (1) | KR100400480B1 (es) |
CN (1) | CN1233417C (es) |
AR (1) | AR002949A1 (es) |
AT (1) | ATE242005T1 (es) |
AU (1) | AU707835B2 (es) |
BR (1) | BR9510102A (es) |
CA (1) | CA2208274C (es) |
CZ (1) | CZ293784B6 (es) |
DE (2) | DE820303T1 (es) |
DK (1) | DK0820303T3 (es) |
ES (1) | ES2201137T3 (es) |
FI (1) | FI118373B (es) |
HR (1) | HRP950612B1 (es) |
HU (1) | HU224160B1 (es) |
IL (1) | IL116499A0 (es) |
IS (1) | IS1966B (es) |
MX (1) | MX9704738A (es) |
NO (1) | NO317350B1 (es) |
NZ (1) | NZ301440A (es) |
PL (1) | PL184145B1 (es) |
PT (1) | PT820303E (es) |
RO (1) | RO116777B1 (es) |
RS (1) | RS49517B (es) |
SI (1) | SI0820303T1 (es) |
TR (1) | TR199501630A2 (es) |
TW (1) | TW496872B (es) |
UA (1) | UA42040C2 (es) |
UY (1) | UY24130A1 (es) |
WO (1) | WO1996019236A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
DE69724619T2 (de) * | 1996-05-14 | 2004-07-01 | Winnacker, Ernst-Ludwig, Prof. | Chaperone, die prionproteine binden und zwischen den isoformen prpc und prpsc unterscheiden können |
EP1335741A4 (en) * | 2000-08-25 | 2005-10-26 | Yeda Res & Dev | METHOD FOR THE PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDES (04.03.02) |
IL140233A0 (en) * | 2000-12-11 | 2002-02-10 | Peptor Ltd | Backbone cyclized analogs of heat shock proteins |
WO2003063759A2 (en) | 2002-01-31 | 2003-08-07 | Peptor Ltd. | Hsp peptides and analogs for modulation of immune responses via antigen presenting cells |
CA2595520A1 (en) | 2004-01-28 | 2005-08-11 | Develogen Israel Ltd. | Hsp therapy in conjunction with a low antigenicity diet |
DE102004043750A1 (de) * | 2004-09-10 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität |
CN100352502C (zh) * | 2004-12-29 | 2007-12-05 | 中国药科大学 | 能通过免疫防治ⅰ型糖尿病的重组蛋白和重组基因 |
US8691772B2 (en) | 2005-01-04 | 2014-04-08 | Yeda Research And Development Co. Ltd. | HSP60, HSP60 peptides and T cell vaccines for immunomodulation |
EP1858545A2 (en) * | 2005-03-04 | 2007-11-28 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
EP2295066B1 (en) | 2005-05-25 | 2016-04-27 | CureDM Group Holdings, LLC | Peptides, derivatives and analogs thereof, and methods of using same |
JP4283812B2 (ja) * | 2006-01-06 | 2009-06-24 | 財団法人工業技術研究院 | 重症筋無力症の診断方法およびそのキット |
WO2008064306A2 (en) | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
MX337147B (es) | 2007-08-30 | 2016-02-15 | Curedm Group Holdings Llc | Composiciones y metodos para utilizar peptidos proislet y sus analogos. |
CU23701A1 (es) * | 2008-12-29 | 2011-09-21 | Ct Ingenieria Genetica Biotech | Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i |
CN104203263A (zh) | 2012-03-01 | 2014-12-10 | 耶达研究与发展有限公司 | 利用HSP60衍生肽再生胰岛β细胞 |
WO2013128450A1 (en) | 2012-03-01 | 2013-09-06 | Yeda Research And Development Co. Ltd. | Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes |
CN104418948B (zh) * | 2013-09-10 | 2019-08-16 | 深圳翰宇药业股份有限公司 | 一种制备多肽药物的方法 |
CN104650209B (zh) * | 2013-11-19 | 2018-04-06 | 深圳翰宇药业股份有限公司 | 多肽药物DiaPep277 的合成方法 |
CN104650244B (zh) * | 2015-01-21 | 2017-12-08 | 中国药科大学 | 一种具有降血糖兼调脂作用的表位组合肽及其用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5114844A (en) * | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
-
1995
- 1995-12-20 NZ NZ301440A patent/NZ301440A/xx not_active IP Right Cessation
- 1995-12-20 AU AU46866/96A patent/AU707835B2/en not_active Expired
- 1995-12-20 WO PCT/US1995/016596 patent/WO1996019236A1/en active Search and Examination
- 1995-12-20 JP JP51996596A patent/JP3420245B2/ja not_active Expired - Fee Related
- 1995-12-20 UA UA97063404A patent/UA42040C2/uk unknown
- 1995-12-20 BR BR9510102A patent/BR9510102A/pt active IP Right Grant
- 1995-12-20 RO RO97-01173A patent/RO116777B1/ro unknown
- 1995-12-20 HU HU9901771A patent/HU224160B1/hu active IP Right Grant
- 1995-12-20 EP EP95944502A patent/EP0820303B1/en not_active Expired - Lifetime
- 1995-12-20 CZ CZ19971908A patent/CZ293784B6/cs not_active IP Right Cessation
- 1995-12-20 DE DE0820303T patent/DE820303T1/de active Pending
- 1995-12-20 PT PT95944502T patent/PT820303E/pt unknown
- 1995-12-20 SI SI9530664T patent/SI0820303T1/xx unknown
- 1995-12-20 AT AT95944502T patent/ATE242005T1/de active
- 1995-12-20 ES ES95944502T patent/ES2201137T3/es not_active Expired - Lifetime
- 1995-12-20 CA CA002208274A patent/CA2208274C/en not_active Expired - Lifetime
- 1995-12-20 DK DK95944502T patent/DK0820303T3/da active
- 1995-12-20 MX MX9704738A patent/MX9704738A/es unknown
- 1995-12-20 PL PL95321091A patent/PL184145B1/pl unknown
- 1995-12-20 KR KR1019970704281A patent/KR100400480B1/ko not_active IP Right Cessation
- 1995-12-20 CN CNB95197680XA patent/CN1233417C/zh not_active Expired - Lifetime
- 1995-12-20 DE DE69531004T patent/DE69531004T2/de not_active Expired - Lifetime
- 1995-12-21 RS YU78795A patent/RS49517B/sr unknown
- 1995-12-21 UY UY24130A patent/UY24130A1/es unknown
- 1995-12-21 HR HR950612A patent/HRP950612B1/xx not_active IP Right Cessation
- 1995-12-21 AR AR10071295A patent/AR002949A1/es unknown
- 1995-12-21 IL IL11649995A patent/IL116499A0/xx not_active IP Right Cessation
- 1995-12-21 TR TR95/01630A patent/TR199501630A2/xx unknown
-
1996
- 1996-01-05 TW TW085100088A patent/TW496872B/zh not_active IP Right Cessation
-
1997
- 1997-06-19 IS IS4510A patent/IS1966B/is unknown
- 1997-06-19 FI FI972669A patent/FI118373B/fi not_active IP Right Cessation
- 1997-06-19 NO NO19972849A patent/NO317350B1/no not_active IP Right Cessation
-
2003
- 2003-01-30 JP JP2003022033A patent/JP3554319B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY24130A1 (es) | Peptido p277 analogos, y composiciones farmaceuticas que los comprenden para el tratamiento o diagnostico de diabetes. | |
Lonberg-Holm et al. | Three high molecular weight protease inhibitors of rat plasma. Isolation, characterization, and acute phase changes. | |
RU98118184A (ru) | Пептидные иммуногены для вакцинации и лечения аллергии | |
ES2106721T3 (es) | Uso de amilina o cgrp para el tratamiento de la diabetes mellitus. | |
DE3855479D1 (de) | Hiv-peptide, künstliche hiv-antigene und immuntestsätze | |
BR9810907A (pt) | Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico | |
Jen Chou et al. | The Immune Response of Lewis Rats to Peptide 68–88 of Guinea Pig Myelin Basic Protein: I. T Cell Determinants | |
BR9106303A (pt) | Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla | |
DE69019190D1 (de) | Pankreatische Isletzellen-Antigene, erhalten durch molekulare Klonierung. | |
DE69638024D1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
ATE364701T1 (de) | Immunoreaktive und immunotherapeutische moleküle welche in individuen mit insulin-abhängiger diabetes mellitus interagieren | |
Franklin et al. | The partial amino acid sequence of the major low molecular weight component of two human amyloid fibrils | |
DE3884316D1 (de) | Synthetische Peptide, gegen diese gerichtete Antikörper und deren Verwendung. | |
SE9001105D0 (sv) | New methods foer diagnosis of tuberculosis | |
Lee et al. | Scientific considerations for generic synthetic salmon calcitonin nasal spray products | |
ES2113356T3 (es) | Peptidos con un determinante antigenico caracteristico para alfa-1-micro-globulina. | |
Pootrakul et al. | Hemoglobin Siam α215argβ2: A new α-chain variant | |
KR930703444A (ko) | 어류 황체화 호르몬-방출 호르몬 동족체 | |
Huang et al. | Synthesis and bioactivities of two multiple antigen peptides as potential vaccine against schistosoma | |
KR970705578A (ko) | 신규의 면역피임 펩티드류(new immunocontraceptive peptides) | |
Blackwell et al. | Fast hemoglobin variant in Minahassan people of Sulawesi, Chinese and Thais: α2β256 Gly→ Asp | |
KR910007963A (ko) | pST의 일부분에 대응하는 아미노산 서열을 갖는 펩티드, 그에 대한 항체 및 pST 활성에 효력을 더하는 방법 | |
KR890009972A (ko) | 펩티드, 이의 제조방법, 항체를 수득하기 위한 이의 용도, 및 인간 혈액중의 pai 1 활성을 억제하기 위한 항체의 용도 | |
Zigler et al. | Studies on beta-crystallin from primate lens. | |
SE8901566D0 (sv) | Nya peptider inkluderande en disulfidbindning |